News
-
-
COMMUNIQUÉ DE PRESSE
Market entry in Belgium: cyan AG is launching a cooperation with Orange Belgium and realizing new growth opportunities
cy'an AG and Orange Belgium collaborate on new cybersecurity solutions launching in the Belgian market, providing enhanced protection for customers' digital lives and mobile devices -
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Entering into agreements for the acquisition of a majority stake in OTRS AG by Optimus BidCo AG, an acquisition company of Easyvista SAS, for a purchase price of EUR 17 per share
OTRS AG to be acquired by Optimus BidCo AG for EUR 17 per share, forming a strategic partnership with Easyvista SAS in the IT Service Management market -
COMMUNIQUÉ DE PRESSE
Vita 34 continues to show increasing revenue, improved profitability and stronger cash generation in the third quarter of 2024
Vita 34 AG reports revenue growth of 6.3% to EUR 60.3 million, EBITDA up 77.5% in Q3 2024. Positive cash flow and strong performance despite market challenges -
-
COMMUNIQUÉ DE PRESSE
beaconsmind AG: First Berlin increases price target to EUR 18.50 and continues to rate share as “Buy”
First Berlin increases beaconsmind AG's price target to EUR 18.50, maintaining 'Buy' rating. Recent acquisitions strengthen position in digital transformation and SaaS solutions -
COMMUNIQUÉ DE PRESSE
The Komax Group is making good progress in the implementation of its strategy
Komax Group progresses in strategy implementation, adjusts mid-term targets due to challenging market environment. Strengthened position in China, optimized distribution network, reduced costs. Change in forecast and Executive Committee -
-
COMMUNIQUÉ DE PRESSE
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Protagonist Therapeutics announces selection of PN-881, an oral peptide interleukin-17 antagonist, as a development candidate for immune-mediated skin diseases. IND enabling studies ongoing with Phase I expected in Q425
